|
|
 | | | |
- close
- close
- close
- close
Active Biotech (STO:ACTI) |
FierceBiotech
Mar 6
Comment
Just as Active Biotech's big pharma partner Teva ($TEVA) enrolled the first person in its high-stakes gamble on the third big Phase III study for the oral MS drug laquinimod, the Swedish biotech company announced that it had raked in $43 million...
Wealth Daily
Oct 22
Comment
Active Biotech's partner Ipsen is beginning trials with a drug previously only used for prostate cancer...
Marketwire
Jul 17
Comment
LUND, SWEDEN -- (Marketwire) -- 07/17/12 -- Active Biotech (NASDAQ OMX NORDIC: ACTI) today announced that the European Medicines Agency (EMA) has completed the validation process for the marketing authorization application (MAA) of the medicinal
Marketwire
Jun 4
Comment
LUND, SWEDEN and PARIS -- (Marketwire) -- 06/04/12 -- Phase II Overall Survival data presented at the 2012 ASCO Annual Meeting Active Biotech (NASDAQ OMX NORDIC: ACTI) and Ipsen (Euronext: IPN; ADR: IPSEY) today presented overall survival (OS) data
Marketwire
May 31
Comment
LUND, SWEDEN -- (Marketwire) -- 05/31/12 -- Active Biotech (NASDAQ OMX NORDIC: ACTI) is scheduled to present at the Jefferies 2012 Global Healthcare Conference held June 4-7, 2012 in New York, USA. During the presentation, an update regarding Active
Marketwire
May 29
Comment
LUND, SWEDEN -- (Marketwire) -- 05/29/12 -- Active Biotech invites analysts, investors and media to Capital Markets Day on June 14, 2012. When: Thursday, June 14, 2012 at 2-4 p.m. CET. Where: Spårvagnshallarna, Birger Jarlsgatan 57 A, Stockholm,
Marketwire
May 21
Comment
LUND, SWEDEN and PARIS -- (Marketwire) -- 05/21/12 -- Active Biotech (NASDAQ OMX NORDIC: ACTI) and Ipsen (Euronext: IPN; ADR: IPSEY) today announced that recruitment to the global, pivotal, randomized, double-blind, placebo- controlled phase III
Marketwire
May 18
Comment
LUND, SWEDEN and PARIS -- (Marketwire) -- 05/18/12 -- Active Biotech (NASDAQ OMX NORDIC: ACTI) and Ipsen (Euronext: IPN; ADR: IPSEY) will present tasquinimod (TASQ), their prostate cancer drug candidate, at the scientific conference "2012 ASCO Annual
Marketwire
May 11
Comment
LUND, SWEDEN -- (Marketwire) -- 05/11/12 -- The Annual General Meeting of Active Biotech was held on May 10, 2012. In accordance with the Board of Directors' proposal, it was resolved that no dividend would be paid. In accordance with the Election
Marketwire
Apr 26
Comment
LUND, SWEDEN -- (Marketwire) -- 04/26/12 -- * Laquinimod - submission of application for regulatory approval in the EU planned for second half of 2012 - Phase III data presented at the Annual Meeting of the American Academy of Neurology (AAN) * TASQ
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS|
Error creating thumbnail: convert: unable to open image `/home/wikinvest/src_live_1/mediawiki/images/9/98/New_stock.png': No such file or directory @ blob.c/OpenBlob/2480. convert: unable to open file `/home/wikinvest/src_live_1/mediawiki/images/9/98/New_stock.png' @ png.c/ReadPNGImage/2889. convert: missing an image filename `/home/wikinvest/src_live_1/mediawiki/images/thumb/9/98/New_stock.png/35px-New_stock.png' @ convert.c/ConvertImageCommand/2800. |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
